The efficacy and safety of cupping as complementary and alternative therapy for metabolic syndrome : A systematic review and meta-analysis
Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc..
INTRODUCTION: This systematic review and meta-analysis aimed to assess the efficacy and safety of cupping therapy in patients with metabolic syndrome (MetS).
METHODS: This systematic review focused on patients with MetS and included randomized controlled trials (RCTs) that compared the effects of cupping therapy with control groups. A total of 12 electronic databases were searched from inception until February 03, 2023. The main outcome after the meta-analysis was waist circumference; the others included anthropometric variables, blood pressure, lipid profile, fasting blood glucose level, and high-sensitivity C-reactive protein level. The incidence of adverse events and the follow-up courses were also evaluated. Risk of bias (ROB) was evaluated using ROB 2.0 from the Cochrane Handbook.
RESULTS: This systematic review included five studies involving 489 patients. Some risks of bias were also identified. The meta-analysis revealed a statistically significance in waist circumference (MD = -6.07, 95% CI: -8.44 to -3.71, P < .001, I2 = 61%, τ2 = 3.4), body weight (MD = -2.46, 95% CI: -4.25 to -0.68, P = .007, I2 = 0%, τ2 = 0) and body mass index (MD = -1.26, 95% CI: -2.11 to -0.40, P = .004, I2 = 0%, τ2 = 0) between the cupping therapy and control groups. However, there were no significant results in total fat percentage and blood pressure values. Regarding biochemical markers, cupping significantly lowered the concentration of low-density lipoprotein cholesterol (MD = -3.98, 95% CI: -6.99 to -0.96, P = .010, I2 = 0%, τ2 = 0) but had no significant effect on total cholesterol, triglyceride, high-density lipoprotein cholesterol, fasting blood glucose, and high-sensitivity C-reactive protein. 3 RCTs reported no adverse events.
CONCLUSIONS: Despite some ROB and low to substantial heterogeneity of the included studies, cupping therapy can be considered a safe and effective complementary intervention for reducing waist circumference, body weight, body mass index, and low-density lipoprotein cholesterol in patients with MetS. In the future, well-designed, high-quality, rigorous methodology, and long-term RCTs in this population are required to assess the efficacy and safety of cupping therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:102 |
|---|---|
| Enthalten in: |
Medicine - 102(2023), 13 vom: 31. März, Seite e33341 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wu, Li-Kung [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9007-41-4 |
|---|
| Anmerkungen: |
Date Completed 04.04.2023 Date Revised 16.09.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1097/MD.0000000000033341 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355049449 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355049449 | ||
| 003 | DE-627 | ||
| 005 | 20231226063528.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/MD.0000000000033341 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1183.xml |
| 035 | |a (DE-627)NLM355049449 | ||
| 035 | |a (NLM)37000047 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wu, Li-Kung |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The efficacy and safety of cupping as complementary and alternative therapy for metabolic syndrome |b A systematic review and meta-analysis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.04.2023 | ||
| 500 | |a Date Revised 16.09.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. | ||
| 520 | |a INTRODUCTION: This systematic review and meta-analysis aimed to assess the efficacy and safety of cupping therapy in patients with metabolic syndrome (MetS) | ||
| 520 | |a METHODS: This systematic review focused on patients with MetS and included randomized controlled trials (RCTs) that compared the effects of cupping therapy with control groups. A total of 12 electronic databases were searched from inception until February 03, 2023. The main outcome after the meta-analysis was waist circumference; the others included anthropometric variables, blood pressure, lipid profile, fasting blood glucose level, and high-sensitivity C-reactive protein level. The incidence of adverse events and the follow-up courses were also evaluated. Risk of bias (ROB) was evaluated using ROB 2.0 from the Cochrane Handbook | ||
| 520 | |a RESULTS: This systematic review included five studies involving 489 patients. Some risks of bias were also identified. The meta-analysis revealed a statistically significance in waist circumference (MD = -6.07, 95% CI: -8.44 to -3.71, P < .001, I2 = 61%, τ2 = 3.4), body weight (MD = -2.46, 95% CI: -4.25 to -0.68, P = .007, I2 = 0%, τ2 = 0) and body mass index (MD = -1.26, 95% CI: -2.11 to -0.40, P = .004, I2 = 0%, τ2 = 0) between the cupping therapy and control groups. However, there were no significant results in total fat percentage and blood pressure values. Regarding biochemical markers, cupping significantly lowered the concentration of low-density lipoprotein cholesterol (MD = -3.98, 95% CI: -6.99 to -0.96, P = .010, I2 = 0%, τ2 = 0) but had no significant effect on total cholesterol, triglyceride, high-density lipoprotein cholesterol, fasting blood glucose, and high-sensitivity C-reactive protein. 3 RCTs reported no adverse events | ||
| 520 | |a CONCLUSIONS: Despite some ROB and low to substantial heterogeneity of the included studies, cupping therapy can be considered a safe and effective complementary intervention for reducing waist circumference, body weight, body mass index, and low-density lipoprotein cholesterol in patients with MetS. In the future, well-designed, high-quality, rigorous methodology, and long-term RCTs in this population are required to assess the efficacy and safety of cupping therapy | ||
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Blood Glucose |2 NLM | |
| 650 | 7 | |a C-Reactive Protein |2 NLM | |
| 650 | 7 | |a 9007-41-4 |2 NLM | |
| 650 | 7 | |a Lipoproteins, LDL |2 NLM | |
| 650 | 7 | |a Cholesterol |2 NLM | |
| 650 | 7 | |a 97C5T2UQ7J |2 NLM | |
| 700 | 1 | |a Chen, Yi-Chen |e verfasserin |4 aut | |
| 700 | 1 | |a Hung, Chung-Shan |e verfasserin |4 aut | |
| 700 | 1 | |a Yen, Chih-Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Chang Chien, Chen-Ying |e verfasserin |4 aut | |
| 700 | 1 | |a Ciou, Jian-Ruei |e verfasserin |4 aut | |
| 700 | 1 | |a Torng, Hsiao-Hsiang |e verfasserin |4 aut | |
| 700 | 1 | |a Chang, Yi-Chin |e verfasserin |4 aut | |
| 700 | 1 | |a Hua, Shiuan |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Peng-Nien |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Yuan-Yuan |e verfasserin |4 aut | |
| 700 | 1 | |a Lai, Chun-Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Kung, Yen-Lun |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Huei-Kai |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Zhong-Kui |e verfasserin |4 aut | |
| 700 | 1 | |a Ho, Tsung-Jung |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Medicine |d 1945 |g 102(2023), 13 vom: 31. März, Seite e33341 |w (DE-627)NLM000020737 |x 1536-5964 |7 nnns |
| 773 | 1 | 8 | |g volume:102 |g year:2023 |g number:13 |g day:31 |g month:03 |g pages:e33341 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/MD.0000000000033341 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 102 |j 2023 |e 13 |b 31 |c 03 |h e33341 | ||